Dynamics of aberrant methylation of functional groups of genes in progression of breast cancer

2013 ◽  
Vol 47 (2) ◽  
pp. 267-274 ◽  
Author(s):  
N. A. Skryabin ◽  
E. N. Tolmacheva ◽  
I. N. Lebedev ◽  
M. V. Zavyalova ◽  
E. M. Slonimskaya ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Functional Groups ◽  
Aberrant Methylation

scholarly journals Detection of Aberrant Methylation Genes in Plasma DNA as Predictor of Therapeutic Outcome of Patients with Breast Cancer

2013 ◽  
Vol 24 ◽  
pp. iii29
Author(s):  
J. Martinez-Galan ◽  
B. Torres-Torres ◽  
L. Portollano ◽  
S. Rios ◽  
M.I. Nuñez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Therapeutic Outcome ◽  
Aberrant Methylation ◽  
Plasma Dna

Methylation profiles of genes in breast cancer luminal HER2-negative primary tumor during regional lymphnode metastasis

2021 ◽  
Vol 67 (1) ◽  
pp. 88-94
Author(s):  
A.M. Krasnyi ◽  
S.V. Kurevlev ◽  
A.A. Sadekova ◽  
T.G. Sefikhanov ◽  
V.V. Kometova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Lymph Node Metastasis ◽  
Regional Lymph Node ◽  
Statistical Significance ◽  
Aberrant Methylation ◽  
Primary Tumors ◽  
Node Metastasis ◽  
Lymphnode Metastasis ◽  
Node Metastases

Aberrant methylation is strongly associated with development of cancer, but limited data exist on correlation between methylation and regional lymph node metastasis (RLNM). The aim of this research was to study using of methylation levels of WIF1, RASSF1A, CDO1 and MEST aberrant methylated genes in a primary breast cancer for prediction of regional lymph node metastases. We used MS-HRM (Methylation Sensitive High Resolution Melting) to assess methylation levels. The results were confirmed by pyrosequencing. The study included 66 women with LumA and 46 women with HER2- (LumB-), 22 and 26 of them had metastasis in at least one lymph node respectively. It was found that methylation levels between LumA and LumB subtypes differed significantly in genes: WIF1 (p<0.001), CDO1 (p=0.002) and MEST (p=0.033). In the Lum A subtype statistically significant differences in level of methylation of WIF1 gene between patients with metastases in RLNM and patients without metastases were found (p=0.03). Analysis of tumors longer than 2 cm in the LumA subtype, revealed an increase of statistical significance of WIF1 gene — p=0.009 (AUC (95%CI) = 0.76 (0.59−0.93)). In LumB- subtype RASSF1A, CDO1 and MEST had statistically significant differences in methylation level between groups (p=0.03, p=0.048 and p=0.045 respectively). ROC analysis showed that combining of three genes by logistic regression, AUC (95%CI) was 0.74 (0.6−0.88). Analysis of tumors longer than 2 cm, did not increase statistical significance for these genes (p=0.046; p=0.089 and p=0.076, respectively). Thus, the study of methylation in primary tumors may be useful for prediction of lymph node metastasis, as well as for better understanding of biological process inside breast cancer.

scholarly journals Genome-Wide Methylation Profiling in Canine Mammary Tumor Reveals miRNA Candidates Associated with Human Breast Cancer

Cancers ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 1466
Author(s):  
Su-Jin Jeong ◽  
Kang-Hoon Lee ◽  
A-Reum Nam ◽  
Je-Yoel Cho
Keyword(s):  
Breast Cancer ◽  
Mammary Tumor ◽  
Mononuclear Cells ◽  
Aberrant Methylation ◽  
Canine Mammary Tumor ◽  
Promoter Regions ◽  
Peripheral Blood Mononuclear ◽  
Genome Wide ◽  
Differentially Methylated Genes ◽  
Methylation Profiling

Genome-wide methylation profiling is used in breast cancer (BC) studies, because DNA methylation is a crucial epigenetic regulator of gene expression, involved in many diseases including BC. We investigated genome-wide methylation profiles in both canine mammary tumor (CMT) tissues and peripheral blood mononuclear cells (PBMCs) using reduced representation bisulfite sequencing (RRBS) and found unique CMT-enriched methylation signatures. A total of 2.2–4.2 million cytosine–phosphate–guanine (CpG) sites were analyzed in both CMT tissues and PBMCs, which included 40,000 and 28,000 differentially methylated regions (DMRs) associated with 341 and 247 promoters of differentially methylated genes (DMGs) in CMT tissues and PBMCs, respectively. Genes related to apoptosis and ion transmembrane transport were hypermethylated, but cell proliferation and oncogene were hypomethylated in tumor tissues. Gene ontology analysis using DMGs in PBMCs revealed significant methylation changes in the subset of immune cells and host defense system-related genes, especially chemokine signaling pathway-related genes. Moreover, a number of CMT tissue-enriched DMRs were identified from the promoter regions of various microRNAs (miRNAs), including cfa-mir-96 and cfa-mir-149, which were reported as cancer-associated miRNAs in humans. We also identified novel miRNAs associated with CMT which can be candidates for new miRNAs associated with human BC. This study may provide new insight for a better understanding of aberrant methylation associated with both human BC and CMT, as well as possible targets for methylation-based BC diagnostic markers.

Research progresses on the functional polypeptides in the detection and imaging of breast cancer

2018 ◽  
Vol 6 (17) ◽  
pp. 2510-2523 ◽  
Author(s):  
Jing Zhao ◽  
Huinan Chen ◽  
Yingying Tang ◽  
Hong Chen ◽  
Guifang Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Functional Groups ◽  
Building Blocks ◽  
Significant Interest ◽  
Recognition Elements ◽  
Signal Sources

Polypeptides as functional groups continue to garner significant interest in the detection and imaging of breast cancer, working as recognition elements, signal sources, building blocks and therapeutic reagents, etc.

scholarly journals Aberrant methylation ofTMS1 in small cell, non small cell lung cancer and breast cancer

2003 ◽  
Vol 106 (2) ◽  
pp. 198-204 ◽  
Author(s):  
Arvind Virmani ◽  
Asha Rathi ◽  
Kenji Sugio ◽  
Ubaradka G. Sathyanarayana ◽  
Shinichi Toyooka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Aberrant Methylation ◽  
Small Cell Lung

Aberrant methylation of miR-34b is associated with long-term shiftwork: a potential mechanism for increased breast cancer susceptibility

2014 ◽  
Vol 26 (2) ◽  
pp. 171-178 ◽  
Author(s):  
Ran Liu ◽  
Daniel I. Jacobs ◽  
Johnni Hansen ◽  
Alan Fu ◽  
Richard G. Stevens ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Susceptibility ◽  
Breast Cancer Susceptibility ◽  
Aberrant Methylation ◽  
Potential Mechanism

scholarly journals Genome-wide DNA methylome analysis reveals novel epigenetically dysregulated non-coding RNAs in human breast cancer

2014 ◽  
Author(s):  
Yongsheng Li ◽  
Yunpeng Zhang ◽  
Shengli Li ◽  
Jianping Lu ◽  
Juan Chen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Human Breast Cancer ◽  
Target Genes ◽  
Cpg Islands ◽  
Aberrant Methylation ◽  
Breast Cancers ◽  
Human Breast ◽  
Protein Coding ◽  
Methylome Analysis ◽  
Non Coding Rnas

The development of human breast cancer is driven by changes in the genetic and epigenetic landscape of the cell. Despite growing appreciation of the importance of epigenetics in breast cancers, our knowledge of epigenetic alterations of non-coding RNAs (ncRNAs) in breast cancers remains limited. Here, we explored the epigenetic patterns of ncRNAs in breast cancers via a sequencing-based comparative methylome analysis, mainly focusing on two most popular ncRNA biotypes, long non-coding RNAs (lncRNAs) and miRNAs. Besides global hypomethylation and extensive CpG islands (CGIs) hypermethylation, we observed widely aberrant methylation in the promoters of ncRNAs, which was higher than that of protein-coding genes. Specifically, intergenic ncRNAs were observed to contribute a large slice of the aberrantly methylated ncRNA promoters. Moreover, we summarized five patterns of ncRNA promoter aberrant methylation in the context of genomic CGIs, where aberrant methylation occurred not only on the CGIs, but also flanking regions and CGI sparse promoters. Integration with transcriptional datasets, we found that the ncRNA promoter methylation events were associated with transcriptional changes. Furthermore, a panel of ncRNAs were identified as biomarkers that were able to discriminate between disease phenotypes (AUCs>0.90). Finally, the potential functions for aberrantly methylated ncRNAs were predicted based on similar patterns, adjacency and/or target genes, highlighting that ncRNAs and coding genes coordinately mediated pathways dysregulation in the development and progression of breast cancers. This study presents the aberrant methylation patterns of ncRNAs, which will be a highly valuable resource for investigations at understanding epigenetic regulation of breast cancers.

Frequency of Hsa-miR9 aberrant methylation in metastatic breast cancers.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e21092-e21092
Author(s):  
Paola Parrella ◽  
Anca Florescu ◽  
Massimiliano Copetti ◽  
Roberto Murgo ◽  
Vanna Maria Valori ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Promoter Region ◽  
Regulation Of Gene Expression ◽  
Metastatic Breast ◽  
Mrna Translation ◽  
Normal Breast ◽  
Aberrant Methylation ◽  
Breast Cancer Patients ◽  
Breast Tissues

e21092 Background: MicroRNAs (miRNAs) are a recently discovered class of very small non-coding RNAs involved in the regulation of gene expression by interfereing with mRNA translation. It has been shown that human miR-9 expression levels are reduced in breast cancer samples due to the aberrant methylation of its promoter region . Methods: We analyzed74breast cancer cases treated by surgery at the IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy. Pathological assessment included evaluation of histological type, grade and stage. Estrogen receptor (ER), progesterone receptor (PgR), Ki-67 labeling index and Her2 amplification were also evaluated. Six of the 74 patients showed metastases at the diagnosis, and 8 patients developed metastases during the follow up. The median follow up time for the patients cohort was 44 months (range 28-57+). All metastatic patients (n=14) died from the disease. Genomic DNA extracted from 6 normal breast tissues obtained by reductive mammoplasty, and tumour samples was subjected to bisulphite treatment and the converted DNA was used as a template for MSP using primers specific for the methylated hsa-miR9 sequence. Results: Methylation at the hsa-miR9 promoter region was detected in 33 of 74 (44%) breast tumours and none of the 6 normal breast tissues (p=0.02). Interestingly, hsa-miR9 methylation was significantly more frequent in patients with syncronous or metachronous distant metastases (8 of 14, 57%) as compared with patients free from metastases (11 of 33, 32%) (p=0.02 χ2 Test). In particular, methylation was detected in all 5 tumours showing only bone metastases (100%), whereas methylation was less frequent (33%) in the group characterized by the the presence of visceral metastases (P=0.03 χ2 Test). Conclusions: Our results suggest that hsa-miR9 methylation in breast cancer is associated with tumour metastatic behaviour and might represent a novel biomarker for monitoring breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document